País: Malta
Idioma: anglès
Font: Medicines Authority
TOPOTECAN
Accord Healthcare Limited
L01XX17
TOPOTECAN
CONCENTRATE FOR SOLUTION FOR INFUSION
TOPOTECAN 1 mg/ml
POM
ANTINEOPLASTIC AGENTS
Authorised
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER TOPOTECAN ACCORD 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION TOPOTECAN Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have further questions, ask your doctor or your pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet See section 4. WHAT IS IN THIS LEAFLET: 1. What Topotecan Accord is and what it is used for 2. What you need to know before you are given Topotecan Accord 3. How to use Topotecan Accord 4. Possible side effects 5. How to store Topotecan Accord 6. Contents of the pack and other information 1. WHAT TOPOTECAN ACCORD IS AND WHAT IT IS USED FOR WHAT TOPOTECAN ACCORD IS: Topotecan Accord helps to destroy tumours. A doctor or a nurse will give you the medicine as an infusion into a vein (a drip) in hospital. WHAT TOPOTECAN ACCORD IS USED FOR: Topotecan Accord is used to treat: - ovarian cancer or small cell lung cancer that has come back after chemotherapy - advanced cervical cancer if surgery or radiotherapy treatment is not possible. When treating cervical cancer, Topotecan Accord is combined with another drug called cisplatin. Your doctor will decide with you whether Topotecan Accord therapy is better than further treatment with your initial chemotherapy. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN TOPOTECAN ACCORD DO NOT TAKE TOPOTECAN ACCORD: - if you are allergic (hypersensitive) to topotecan or any of the other ingredients of Topotecan Accord (listed in section 6). - if you are breast feeding - if your blood cell counts are too low. Your doctor will tell you, based on the results of your last blood test. TELL YOUR DOCTOR if any of these applies to you. WARNING AND PRECAUTIONS Talk to you doctor or pharmacist or nurse before you are given this medicine: - if you have any kidney or liver problems. Your Llegiu el document complet
Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Topotecan Accord 1 mg/ml concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride). Each 1 ml vial of concentrate contains 1 mg topotecan (as hydrochloride) Each 4 ml vial of concentrate contains 4 mg topotecan (as hydrochloride) For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. A clear yellow colour solution free from visible foreign particles. pH in the range of 1.5 to 2.5 and Osmolarity in the range of approximately 100 to 40 mOsm/Litre. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Topotecan monotherapy is indicated for the treatment of: • Patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. • Patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first- line regimen is not considered appropriate (see section 5.1). Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY When used in combination with cisplatin, the full prescribing information for cisplatin should be consulted. Page 2 of 14 Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of 1.5 x 10 9 /l, and a platelet count of 100 x 109/l and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary). _OVARIAN AND SMALL CELL LUNG CARCINOMA _ _ _ _INITIAL DOSE _ The recommended dose of topotecan is 1.5 mg/m 2 body surface area/day administered by intravenous infusion over 30 minutes daily for 5 consecutive days with a 3 week interval between the start of each course. Llegiu el document complet